Genmab A/S Total Liabilities

The latest total liabilities for GNMSF is $6.6B as of June 2026. That compares with $1.2B in the prior-year period — up 464.4% year over year. Investors often review this figure alongside Genmab A/S's historical trend and sector peers before judging valuation or financial health.

Over the past year, GNMSF's total liabilities moved from $1.2B to $6.6B — a 464.4% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Genmab A/S's operating scale or balance-sheet position.

A total liabilities figure of $6.6B for GNMSF is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting GNMSF's total liabilities ($6.6B), review year-over-year change from $1.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Genmab A/S's total liabilities against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.